[Knoxville, TN] November 2023: NellOne Therapeutics, Inc. (NellOne), an innovative biopharmaceutical company specializing in groundbreaking regenerative medicine, is pleased to announce its recent membership with the Knoxville Chamber.

“The Knoxville Chamber’s mission is to drive regional economic prosperity, and we prioritize support for existing businesses and startups. Creating an environment where companies want to start, grow, and remain is our goal,” said Vice President of Investor Development and Experience, Mark Field. “I am thankful NellOne sees the value in our work, including pro-business advocacy, expansion support, talent retention, and more. A rising tide lifts all boats, and NellOne’s investment not only impacts their organization but the entire community. Our region is uniquely positioned to support biotech startups and we believe companies like NellOne will lead the way in transitioning Knoxville’s economy in preparation for the next industrial revolution.”

The Knoxville Chamber connects members, also known as investors, with resources and services designed to meet their individual needs. The Chamber prioritizes support to early-stage companies, like NellOne, to help them start, grow, and remain in Knoxville.

“Joining the Knoxville Chamber aligns with NellOne’s mission, as the Chamber’s commitment to innovation and entrepreneurship through its ‘Path to Prosperity’ initiative fosters an ideal environment for the growth of biotech firms like ours. We’re proud to support and be part of this thriving community,” said NellOne CEO, Bill Malkes.

To learn more about the Knoxville Chamber visit knoxvillechamber.com.

About NELLONE Therapeutics

At NellOne, we specialize in the innovation of NV1, a patented form of the NELL1 protein designed to transform the therapeutic landscape across various medical applications. NV1 exhibits a unique, context-specific mechanism of action that is still being unraveled. It works within the body’s extracellular matrix to recalibrate critical biological processes, ensuring the restoration and maintenance of healthy tissue functions.

The protein’s profound impact is evident as it modulates immune responses, alleviates hypoxia, and promotes new blood vessel formation, fostering an environment conducive to tissue repair and regeneration. NV1 has shown promising results in inflammatory respiratory diseases, demonstrating its ability to diminish inflammation and improve survival in rigorous pre-clinical studies.

Further research has revealed NV1’s potential in diabetic wound care, cardiac tissue repair, and the maintenance of precursor cells for advanced diagnostic and therapeutic uses, marking it as a versatile agent in medical science’s quest to heal and restore the human body.

Please visit https://nell-one.com/.